FluoGuide has enrolled the first patient in the phase IIb trial in aggressive brain cancer
Copenhagen, Denmark, 20 October 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the first patient has now enrolled in the phase IIb clinical trial with FG001 in aggressive brain cancer.In the phase IIb trial, FG001 is being tested as a standalone treatment compared to Gliolan (5-ALA), which is the only approved product for intraoperative guidance during aggressive brain cancer surgery. 24 patients will be randomized 1:1 against Gliolan (5-ALA). The primary endpoint of the phase IIb trial measures the proportion of patients with relevant change in clinical